Lasmiditan, sold under the trade name Reyvow, is a medication used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not useful for prevention. It is taken by mouth.
|By mouth, intravenous|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||377.36 g/mol g·mol−1|
|3D model (JSmol)|
Common side effects include sleepiness, dizziness, tiredness, and numbness. It is a "neurally acting anti-migraine agent" ditan.
Lasmiditan was approved in the United States in October 2019. It was developed by Eli Lilly. As of October 2019, the medication is not available and the proposed price is unclear.
Mechanism of action
Lasmiditan is a serotonin receptor agonist that, like the unsuccessful LY-334,370, selectively binds to the 5-HT1F receptor subtype. A number of triptans have been shown to act on this subtype as well, but only after their affinity for 5-HT1B and 5-HT1D has been made responsible for their anti-migraine activity. The lack of affinity for these receptors might result in fewer side effects related to vasoconstriction compared to triptans in susceptible patients, such as those with ischemic heart disease, Raynaud's phenomenon or after a myocardial infarction, although a 1998 review has found such side-effects to rarely occur in patients taking triptans.
There is a risk of driving impairment while taking lasmiditan. People are advised not to drive or operate machinery for at least eight hours after taking lasmiditan, even if they feel well enough to do so. People who cannot follow this advice are advised not to take lasmiditan. The drug causes central nervous system (CNS) depression, including dizziness and sedation. It should be used with caution if taken in combination with alcohol or other CNS depressants.
Lasmiditan was discovered by Eli Lilly and Company and was then relicensed to CoLucid Pharmaceuticals in 2006, until CoLucid was bought by Eli Lilly in 2017 to allow Eli Lilly to reacquire the drug's intellectual property. The drug is protected by patents until 2031.
Phase II clinical trials for dose finding purposes were completed in 2007 for an intravenous form and in early 2010 for an oral form. Eli Lilly submitted a new drug application to the FDA in November 2018.
Three phase III clinical trials were completed. The SPARTAN trial compared placebo with 50, 100, and 200 mg of lasmiditan. SAMURAI compared placebo with 100 and 200 mg doses of lasmiditan. GLADIATOR is an open-label study that compared 100 and 200 mg doses of lasmiditan in patients that received the drug as part of a prior trial.
Topline results from the SPARTAN trial showed that the drug induced met its primary and secondary endpoints in the trial. The primary result showed a statistically significant improvement in pain relief relative to placebo 2 hours after the first dose. The secondary result showed a statistically significantly greater percentage of patients were free of their most bothersome symptom (MBS) compared with placebo at two hours following the first dose.
The FDA approved the drug on 11 October 2019. However, the drug is awaiting Drug Enforcement Administration (DEA) scheduling before it is made available in the United States.
- "FDA approves new treatment for patients with migraine". U.S. Food and Drug Administration (FDA) (Press release). 11 October 2019. Archived from the original on 16 November 2019. Retrieved 17 October 2019.
This article incorporates text from this source, which is in the public domain.
- "Lilly's 1-drug migraine business gets support with new approval". BioPharma Dive. 11 October 2019. Retrieved 17 October 2019.
The Drug Enforcement Administration is currently reviewing Reyvow for controlled substance classification, a typically 90-day process after which the treatment will be available in retail pharmacies.
Lilly did not disclose a price at approval, saying cost information would be released nearer to market launch.
- "Molecule of the Month July 2010: Lasmiditan hydrochloride". Prous Science. Retrieved 3 August 2011.
- Dahlöf, CG; Mathew, N (1998). "Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern?". Cephalalgia: An International Journal of Headache. 18 (8): 539–45. doi:10.1046/j.1468-2982.1998.1808539.x. PMID 9827245.
- Mutschler, Ernst; Geisslinger, Gerd; Kroemer, Heyo K.; Schäfer-Korting, Monika (2001). Arzneimittelwirkungen (in German) (8th ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. p. 265. ISBN 978-3-8047-1763-3. OCLC 47700647.
- "REYVOW- lasmiditan tablet". DailyMed. 11 October 2019. Retrieved 15 November 2019.
- Clinical trial number NCT00384774 for "A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine" at ClinicalTrials.gov
- Clinical trial number NCT00883051 for "Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment" at ClinicalTrials.gov
- "Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache". Eli Lilly and Company. 14 November 2018. Retrieved 12 October 2019 – via PR Newswire.
- Clinical trial number NCT02605174 for "Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine (SPARTAN)" at ClinicalTrials.gov
- Clinical trial number NCT02565186 for "An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine (GLADIATOR)" at ClinicalTrials.gov
- Vinluan, Frank (11 October 2019). "FDA OKs Lilly's Lasmiditan, First New Acute Migraine Drug in Decades". Xconomy. Retrieved 12 October 2019.
- "Lasmiditan". Drug Information Portal. U.S. National Library of Medicine.